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Abstract
Co-occurrence of multiple neuropathologic changes is a common phenomenon, most prominently seen in
Alzheimer’s disease (AD) and Parkinson’s disease (PD), complicating clinical diagnosis and patient management.
Reports of co-occurring pathological processes are emerging in the group of genetically defined repeat-associated
non-AUG (RAN)-translation related diseases. Here we report a case of Fragile X-associated tremor-ataxia syndrome
(FXTAS) with widespread and abundant nuclear inclusions of the RAN-translation related FMRpolyG-peptide. In
addition, we describe prominent neuronal and glial tau pathology representing changes seen in progressive
supranuclear palsy (PSP). The highest abundance of the respective pathological changes was seen in distinct brain
regions indicating an incidental, rather than causal correlation.
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Introduction
Fragile X-associated tremor-ataxia syndrome (FXTAS) was
first discovered in 2001 and has emerged as a unique late
onset ataxia with often characteristic imaging features [9,
11, 17]. FXTAS is caused by a premutation expansion in
the trinucleotide CGG repeat (50–200 repeats) in the fragile
X mental retardation 1 (FMR1) gene. Patients typically
present from 60 to 65 years of age with tremor and/or gait
ataxia and a spectrum of associated neurologic and medical
symptoms [9]. Diagnostic criteria also include pathogno-
monic neuroimaging and neuropathological findings [1, 8,
10]. The intranuclear sequestration of proteins by expanded
CGG repeats in FMR1 mRNA has been suggested as a trig-
gering pathogenic event [7]. In addition, non-AUG-initiated
(RAN) translation of the expanded CGG repeats into a
polyglycine-containing peptide (FMRpolyG) that is prone
to aggregate has been implicated in neurotoxicity [2, 3, 15,
18]. These aberrant protein inclusions can also trigger the
aggregation of other proteins. Indeed, there have been
reports of the co-occurrence of FXTAS with Lewy body de-
mentia (LBD) and Alzheimer’s disease (AD) [16]. We now
report a patient with FXTAS and neuropathological evi-
dence of co-occurring progressive supranuclear palsy (PSP).
Case presentation
A 65-year-old Caucasian male was followed in the ataxia
clinic at the Center for Movement Disorders and Neuro-
restoration at the University of Florida who had a 10-year
history of gradually progressive bilateral upper extremity
postural tremor and action myoclonus, bradykinesia,
memory impairment, and an unsteady gait with frequent
forward falls. On exam he had no vision abnormalities or
gaze palsies and normal muscle strength with intact sensa-
tion, but limited cervical rotation due to neck muscle stiff-
ness. MRI revealed FLAIR and T2 hyperintensities in the
middle cerebellar peduncles extending into the deep white
matter of the cerebellum as well as generalized atrophy.
Given that the patient’s clinical presentation and imaging
were suggestive of FXTAS, further genetic testing was
completed which showed 96 CGG trinucleotide repeats in
the FMR1 gene. By age 68, he had diffuse myoclonus and
a severely ataxic gait requiring the use of a wheelchair,
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inability to perform activities-of-daily-living due to impair-
ment of executive functioning, dysarthria, dysmetria,
hypomimia, incontinence, and constipation. He died at
the age of 69.
Central nervous system autopsy was performed with
post-mortem interval of 3 h. The brain weighed 1235 g
and gross examination revealed gray discoloration of the
cerebellar peduncles and deep cerebellar white matter.
There was mild hypopigmentation of the substantia nigra.
Routine H&E and Luxol-fast blue-H&E stains were ex-
amined and immunohistochemical studies for tau (PHF-1,
Peter Davies, 1:500; AT-8, Fisher 1:250; RD4, Millipore, 1:
1000), α-synuclein (pSer 129, 81A [19] 1:5000), Aβ (33.1.1;
1:1000), TDP-43 (pSer409/410; Proteintech 1:1000), ubi-
quitin (Abcam, 1:500), p62 (Proteintech 1:250), GFAP
(Promega, 1:1000), and RAN translation product specific
antibodies NTF1 ([12]; 1:400) and CTF1 ([12]; 1:40) were
performed. There was prominent spongiosis in the deep
cerebellar white matter and middle cerebellar peduncles
(Fig. 1a). Spongiosis was also present in the centrum semi-
ovale and subcortical white matter of the cingulate gyrus.
Abundant eosinophilic intranuclear inclusions were identi-
fied by routine H&E staining (Fig. 1b, arrows). These inclu-
sions were immunoreactive for ubiquitin, p62 (Fig. 1c),
NTF1 (Fig. 1d), a polyclonal antibody raised against the N-
terminus of the FMRpolyG RAN translation product and
focally also with CTF1 (Fig. 1e), a polyclonal antibody
raised against the C-terminus of the FMRpolyG RAN
translation product ([12] and accompanying manuscript
ANEC-D-19-00289). These aggregates were found within
neurons and protoplasmic astrocytes of the cerebral cortex,
brainstem, cerebellum, and cervical spinal cord. Intranuc-
lear inclusions were especially numerous in hippocampal
dentate neurons, pyramidal neurons of CA3 and CA4
(Fig. 1 c, d, e), pontine nuclei (Fig. 1f) and frontal neo-
cortical neurons. Foci of the cerebellar cortex showed
Purkinje cell loss and intranuclear inclusions of Berg-
mann glia as well as rare Purkinje neurons (Fig. 1g).
An immunocytochemical study for tau with AT8 and
RD4 (4-repeat tau) antibodies demonstrated tufted astro-
cytes (Fig. 2a), globose neurofibrillary tangles (Fig. 2b) and
oligodendroglial “coiled bodies” (Fig. 2c) in the basal gan-
glia, subthalamic nucleus, substantia nigra, amygdala, and
medulla. In the substantia nigra and the locus coeruleus,
tau pathology was associated with mild to moderate neur-
onal loss. No Aβ-amyloid, α-synuclein, or TDP-43 path-
ology was observed by immunohistochemical study.
Plotting the relative abundance (0 = no pathology; 1 =mild
pathology; 2 =moderate pathology and 3 = severe path-
ology) of intranuclear pathology (NTF1 and p62 staining)
and tau pathology (AT8 staining), we noted a remarkable
correlation between NTF1 staining and p62 staining (Fig.
2d, [12]). In contrast, areas with the most abundant tau
pathology (lentiform nucleus and subthalamic nucleus)
Fig. 1 Neuropathology of FXTAS. Luxol fast blue-H&E stain shows spongiosis of the cerebellar white matter (a). Abundant eosinophilic
intranuclear inclusions (arrows) were found in neurons of the cerebral cortex, especially in hippocampal pyramidal cells (b). Intranuclear inclusions
in the CA4 region of the hippocampus were immunorective for p62 (c), NTF1 (d) and CTF1 (e). Neurons and glia in pontine nuclei (f NTF1), as
well as Bergmann glia and rare Purkinje neurons of the cerebellum also contained intranuclear inclusions (g NTF1). [Scale bar = 100 μm in a;
20 μm in b, c, d, e, f and g]
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showed only minimal intranuclear pathology and vice
versa (Fig. 2d).
Discussion and conclusions
Patients with FXTAS may occasionally present with PSP-
like clinical findings [5], and a recent case report showed
co-occurrence of FXTAS with PSP neuropathological
findings [14]. We have expanded upon these findings and
report a case of abundant FXTAS pathology with co-
occurring PSP-like tau pathology. Clinically, the patient
had symptoms of FXTAS with tremor and ataxia with the
addition of PSP-like symptoms of bradykinesia, postural
instability, dysarthria, and executive dysfunction. However,
there was no evidence of truncal rigidity or supranuclear
gaze palsy [6]. Neuropathological study revealed classic
changes of FXTAS including white matter pallor and
spongiosis in the cerebellum and cerebrum along with
widespread intranuclear ubiquitin, p62, and FMRpolyG
positive inclusions [7, 8, 12]. Additionally, the patient had
tau pathology including globose NFTs in the substantia
nigra, locus coeruleus, medulla, and basal ganglia with
tufted astrocytes and oligodendroglial coiled bodies
composed of 4-repeat tau, which are consistent with PSP
neuropathology, and given the overall low abundance
possibly reflecting “incidental PSP” [4]. Cross-seeding of
misfolded proteins has been suggested as a possible mech-
anism for the co-occurrence of multiple pathologies in
neurodegenerative diseases [13], but whether our case re-
flects the incidental co-occurrence of two distinct neuro-
degenerative processes or is the consequence of a cross-
talk between two distinct neurodegenerative processes
cannot be determined with certainty. The fact that the
highest abundance of the respective neuropathological
changes was detected in non-overlapping brain regions
may favor two independent processes.
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Fig. 2 PSP-like changes were detected by AT8 immunohistochemistry as tufted astrocytes (a), globose tangles (b) and coiled bodies (c). (d)
Heatmap of relative abundance of NTF1-positive pathology (upper row), AT-8 positive pathology (middle row) and p62-positive pathology (lower
row). 0 = no pathology, 1 = mild pathology, 2 = moderate pathology and 3 = severe pathology). Scale bar: 20 μm
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